

JUN 04 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: Amin Kassis

Examiner: Jon P. Wever

Serial No: 09/839,779

Group Art Unit: 1651

Filed: April 20, 2001

For: Methods for Tumor Diagnosis and Therapy

I CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED  
WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL IN AN  
ENVELOPE ADDRESSED TO **MAIL STOP NON-FEE AMENDMENT**,  
COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450

ON

5/24/03

BY

Amine Kassis

RECEIVED

JUN 04 2003

**MAIL STOP NON-FEE AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TECH CENTER 1600/2900

Dear Sir:

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Enclosed herewith is an Supplemental Information Disclosure Statement pursuant to 37 CFR. § 1.56 in connection with the above-identified application, which statement is being filed:

Together with the present application.

Before the first Office Action on the merits or three (3) months from the filing date of this application, whichever occurs last. [37 CFR § 1.97(b)]

After the first Office Action on the merits, but before a Final Office Action under §1.113 or Notice of Allowance under §1.311, whichever occurs first. [37 CFR §1.97(c)]. (Either the fee or certification is provided, as set forth below).

After a Final Office Action under §1.113 or Notice of Allowance under §1.311, but prior to or with payment of the Issue Fee. [37 CFR §1.97(d)]. The fee and certification are provided, as set forth below).

Consistent with Applicant's obligations pursuant to 37 CFR §§1.97 and 1.98, the following requirements have been met:

- [ ] No separate requirements are needed.
- [X] No additional fee is required.

**Fee Under 37 CFR § 1.97(c) or 1.97(d)**

[ ] The fee of \$180.00 for submission of an IDS under § 1.97(c) as set forth in § 1.17(p) accompanies this statement.

**Certification Under 37 CFR § 1.97(e)**

The undersigned certifies:

[ ] 1 that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

[ XX ] 2 that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement.

**Provision of Copies of References**

[ X] A copy of each of the references listed on the attached Form PTO-1449 is enclosed herewith and forms a part hereof.

[ ] A translation of Reference \_\_\_\_ is enclosed herewith and forms a part hereof.

[ ] A copy of the European Search Report from a corresponding or related EPO application is enclosed herewith.

[ ] A copy of the International Search Report from a corresponding or related PCT application is enclosed herewith.

**Identification of Prior Application(s) In Which Listed Information Was Already Cited And  
For Which No Copies Are Submitted Or Need Be Submitted**

[ ] This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior U.S. Application No(s). , filed . The following references were submitted to, and/or cited by, the Office in the prior application(s) and therefore are not required to be provided in this application:

The Commissioner is hereby authorized to charge any fees associated with this communication or credit any overpayment to Deposit Account No. 04-1679.

Respectfully submitted,

Date: 5/29/03

*Melanie S. McPeek, Goddard*  
Melanie S. McPeek Goddard  
Registration No. 46,732

DUANE MORRIS LLP  
One Liberty Place  
Philadelphia, PA 19103-7396  
215-979-1310 tel  
215-979-1020 fax

